Ivan Maslev’s research while affiliated with Medical University of Sofia and other places

Viral epidemics are constant satellite of human civilization and for millennia, the only achievement of common sence has been quarantine. Unlike in the time of dark days knowledge about the new coronavirus was gained almost lightning-fast. Its genetic code was read within days following the start of the epidemic in Wuhan. The structure of the virus together with electron microscopic identification has been widely available to scientific and public attention. We are convinced that with the capabilities of modern biophysics on the basis of the original BMT methodology automated systems can be created. They will be able to provide an opportunity for effective and affordable treatment of many infectious diseases.

The current presentation displays chronologically our summarized and updated results of more than 12 years of the accumulated experience of integrative oncology application in our medical practice. Based on our concept of systemic approach, we have created treatment protocol for cancer patients with leading method of administering Insulin Potentiation Therapy (IPT). For the past 12 years period we treated more than 1100 cancer patients, greater part of which (94%) were patients with advanced metastatic tumors (Т2-Т4) and more than 80% of them experienced failure of previous conventional treatment for cancer with chemo-and radiotherapy. The achieved treatment results demonstrated remission in about 80% of the patients, and were presented in our earlier publications. In search for new opportunities of improvement of our treatment efficiency since April 2018, we created treatment method which includes combination of IPT with Biomagnetic therapy with magnetic pairs. (IPT & BMP). Until August 2019 this specific treatment has been applied to 33 cancer patients with advanced metastatic tumors (Т2-Т4) in which 19 out of 23 (82%) experienced failure of previous standard treatment. Twenty-three patients have completed their treatment and were followed up by us. Out of them, 5 patients (21%) have achieved complete remission, and 17 patients (74%) have achieved stabilization. The average remission period is 10 months up till now. Registered failed treatment is present in only one case. Illustrating the opportunities of the new method, we present herewith two new cases with the results of complete clinical remission. In our opinion, the results are an illustration of the opportunities of the Integrative oncology, and the need for change in the concept for cancer patients' treatment.

Purpose. To evaluate the results and quality of life of patients with resistant of castration-resistant tumors previously treated with Insulin-potentiation therapy (IPT) combined with hormone therapy. Materials and methods. Sixteen patients with metastasis prostate tumors after bilateral castration, androgenic blockade, and progression of the disease were observed during the study. The patients were divided into two groups: group A consisting of 8 patients treated with low-dose chemotherapy Epirubicin, Vinblastine, and Cyclophosphamide combined with LHRH agonist and group B consisting of another 8 patients treated with low-dose chemotherapy Docetaxel combined with LHRH agonist. Results. The overall (groups A and B) results concerning PSA after the sixth IPT show partial effect in 8 out of 16 (50%) patients, stabilization in 4 out of 16 (25%), and progression in 4 out of 16 (25%). The median survival for all treated patients is 11,7 months (range 3-30 months). During the treatment no significant side effects were observed, and no lethal cases occurred. Conclusion. In spite of the small number of the treated patients with castration-resistant prostate tumors, the preliminary results are promising and this gives us hope and expectations for future serious multicenter research over the possibilities for routine implementation of IPTLD.